- Conditions
- Bladder Cancer, Glioma, Glioblastoma (GBM), Breast Cancer, Colorectal Cancer, Esophageal Cancer, Gastric Cancer (GC), Pharynx Cancer, Oral Cavity Cancer, Kidney Cancer, Liver Cancer, Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Cancer, PDAC - Pancreatic Ductal Adenocarcinoma, Prostate Cancer
- Interventions
- [64Cu]CM500, [68Ga]CM500, PET/MR, PET/CT, Blood Collection
- Drug · Device · Procedure
- Lead sponsor
- Lumina Pharmaceuticals Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • Grand Rapids, Michigan • New York, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 540
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma, Metastatic Laryngeal Squamous Cell Carcinoma, Metastatic Oral Cavity Squamous Cell Carcinoma, Metastatic Oropharyngeal Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Neck Squamous Cell Carcinoma of Unknown Primary, Recurrent Oral Cavity Squamous Cell Carcinoma, Recurrent Oropharyngeal Squamous Cell Carcinoma, Refractory Head and Neck Squamous Cell Carcinoma, Refractory Hypopharyngeal Squamous Cell Carcinoma, Refractory Laryngeal Squamous Cell Carcinoma, Refractory Oral Cavity Squamous Cell Carcinoma, Refractory Oropharyngeal Squamous Cell Carcinoma, Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage IV Hypopharyngeal Carcinoma AJCC v8, Stage IV Laryngeal Cancer AJCC v8, Stage IV Lip and Oral Cavity Cancer AJCC v8, Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8
- Interventions
- Biospecimen Collection, Cetuximab, Computed Tomography, Magnetic Resonance Imaging, Pembrolizumab, Positron Emission Tomography
- Procedure · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 158 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 200
- States / cities
- Little Rock, Arkansas • Marysville, California • Palo Alto, California + 161 more
- Conditions
- Head and Neck Cancer
- Interventions
- ZD 1839 500mg
- Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2018
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Laryngeal Squamous Cell Carcinoma, Stage II Laryngeal Cancer AJCC v8, Stage III Laryngeal Cancer AJCC v8
- Interventions
- Carboplatin, Cisplatin, Docetaxel, Pembrolizumab
- Drug · Biological
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Pain, Bladder Cancer, Breast Cancer, CNS Cancer, Colon Cancer, Esophageal Cancer, Pancreatic Cancer, Prostate Cancer, Uterine Cancer, Head and Neck Cancer, Eye Cancer, Otorhinolaryngologic Neoplasms
- Interventions
- D-methadone, placebo
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2008
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Dysphagia, Head and Neck Cancer, Mucositis, Xerostomia
- Interventions
- exercise intervention, amifostine trihydrate, therapeutic dietary intervention
- Behavioral · Drug · Procedure
- Lead sponsor
- Vanderbilt-Ingram Cancer Center
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Oropharyngeal Cancer
- Interventions
- Not listed
- Lead sponsor
- Sanford Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 2
- States / cities
- Fargo, North Dakota • Sioux Falls, South Dakota
- Conditions
- Nasopharyngeal Carcinoma
- Interventions
- Genetically modified CTLs
- Biological
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- Not listed
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2013
- U.S. locations
- 2
- States / cities
- Houston, Texas
- Conditions
- Head and Neck Cancer
- Interventions
- porfimer sodium, fluorophotometry
- Drug · Other
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1995
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Head and Neck Cancer, Kidney Cancer, Neuroblastoma, Ovarian Cancer, Sarcoma, Testicular Germ Cell Tumor
- Interventions
- filgrastim, temozolomide, peripheral blood stem cell transplantation
- Biological · Drug · Procedure
- Lead sponsor
- Duke University
- Other
- Eligibility
- Up to 18 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2005
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Paranasal Sinus Cancer, Nasal Cavity Tumor, Nasal Cavity Adenocarcinoma
- Interventions
- Cisplatin, Adjuvant Proton Radiotherapy, Endoscopic Resection, cisplatin and etoposide
- Drug · Radiation · Procedure
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 5
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 2 more
- Conditions
- Oral Cavity Cancer, Oropharyngeal Cancer
- Interventions
- Oral examination with incandescent light, Oral examination with OralID, Biopsy, CytID, hpvID
- Other · Diagnostic Test
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Cancer of the Pharynx, Cancer of the Larynx, Cancer of the Neck, Paranasal Sinus Neoplasms, Cancer of the Head
- Interventions
- erlotinib + celecoxib
- Drug
- Lead sponsor
- Johnny Kao
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- EBV Infection, Stage II Nasopharyngeal Carcinoma AJCC v7, Stage III Nasopharyngeal Carcinoma AJCC v7, Stage IVA Nasopharyngeal Carcinoma AJCC v7, Stage IVB Nasopharyngeal Carcinoma AJCC v7
- Interventions
- Bone Scan, Cisplatin, Clinical Observation, Computed Tomography, Fluorouracil, Gemcitabine Hydrochloride, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Paclitaxel, Positron Emission Tomography, Quality-of-Life Assessment
- Procedure · Drug · Other + 1 more
- Lead sponsor
- NRG Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 924 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2031
- U.S. locations
- 197
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Auburn, California + 150 more
- Conditions
- Cancer of Larynx
- Interventions
- Cisplatin, Cetuximab, 5-Fluorouracil, Docetaxel
- Drug
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Nasopharyngeal Carcinoma
- Interventions
- Epstein-Barr virus-specific adoptive T-cells immunotherapy
- Biological
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2016
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Hypertrophic Cardiomyopathy, Hearing Loss, Cancer
- Interventions
- GeneInsight Clinic (GIC)
- Device
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- Not listed
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2014
- U.S. locations
- 8
- States / cities
- Boston, Massachusetts • Ann Arbor, Michigan
- Conditions
- Oropharynx Cancer, HPV-Related Carcinoma
- Interventions
- Radiation, Platinum based chemotherapy
- Radiation · Drug
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- CNS Cancer, Meningioma, Intracranial Hemangiopericytoma, Hemangioblastoma, Neurofibromatosis
- Interventions
- Sunitinib
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2014
- U.S. locations
- 6
- States / cities
- Boston, Massachusetts • Basking Ridge, New Jersey • Commack, New York + 3 more
- Conditions
- Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma, Metastatic Laryngeal Squamous Cell Carcinoma, Metastatic Lip and Oral Cavity Carcinoma, Metastatic Nasal Cavity Squamous Cell Carcinoma, Metastatic Nasopharyngeal Squamous Cell Carcinoma, Metastatic Pharyngeal Squamous Cell Carcinoma, Metastatic Sinonasal Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Lip and Oral Cavity Squamous Cell Carcinoma, Recurrent Nasopharyngeal Squamous Cell Carcinoma, Recurrent Pharyngeal Squamous Cell Carcinoma, Recurrent Sinonasal Squamous Cell Carcinoma, Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage IV Hypopharyngeal Carcinoma AJCC v8, Stage IV Laryngeal Cancer AJCC v8, Stage IV Lip and Oral Cavity Cancer AJCC v8, Stage IV Nasopharyngeal Carcinoma AJCC v8, Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IV Sinonasal Cancer AJCC v8
- Interventions
- Atezolizumab, Bevacizumab, Biospecimen Collection, Carboplatin, Cetuximab, Cisplatin, Computed Tomography, Docetaxel, Echocardiography Test, Magnetic Resonance Imaging, Positron Emission Tomography
- Biological · Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 430 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 172
- States / cities
- Little Rock, Arkansas • Dublin, California • Emeryville, California + 135 more
- Conditions
- Mucositis, Nephrotoxicity, Ototoxicity
- Interventions
- Tempol, Placebo Solution
- Drug
- Lead sponsor
- Matrix Biomed, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 9
- States / cities
- La Jolla, California • Merced, California • San Francisco, California + 4 more
- Conditions
- Sinonasal Neuroendocrine Carcinoma, Nasopharyngeal Carcinoma, Esthesioneuroblastoma, Olfactory Neuroblastoma, Somatostatin Receptor Positive, Small Cell Lung Cancers, Pheochromocytoma/Paragangliomas, Kidney Cancers, Head and Neck Tumors, Gastrointestinal Neuroendocrine Tumors
- Interventions
- 68Ga-DOTATATE, [203Pb]VMT-alpha-NET, [212Pb]VMT-alpha-NET
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Oropharyngeal Human Papillomavirus-Positive Squamous Cell Carcinoma
- Interventions
- Transoral Surgery, External Beam Radiation Therapy, Cisplatin, Incisional Tumor Biopsy, Circulating tumor deoxyribonucleic acid (ctDNA) levels assessment, MD Anderson Dysphagia Index, University of Washington Quality of Life Questionnaire, Euro-QOL 5 dimension scale questionnaire, Modified barium swallow (MBS) evaluation with aspiration-penetration scale
- Procedure · Radiation · Drug + 2 more
- Lead sponsor
- Rutgers, The State University of New Jersey
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 3
- States / cities
- New Brunswick, New Jersey • Newark, New Jersey
- Conditions
- Vaginal Cancer, Cervical Cancer, Anal Cancer, Penile Cancer, Oropharyngeal Cancer
- Interventions
- Fludarabine, Cyclophosphamide, E6 TCR, Aldesleukin
- Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland